AUPH - Aurinia's Successful Study In Lupus Nephritis Changes The Scope Of Treatment Options For Patients
Aurinia Pharmaceuticals (AUPH) announced that it had achieved the primary endpoint for its phase 3 study using its drug voclosporin along with background therapy to treat patients with Lupus Nephritis ((LN)). Not only did the biotech meet on the primary endpoint of the study with statistical significance, but it did so on all secondary endpoints as well. Based on this highly substantial data, I view voclosporin as changing the scope of treatment for this patient population. Especially, when it comes to adverse events being experienced with other drugs. An NDA filing for voclosporin